ArticleOncoTargets and therapy2018

Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine.

Claudia De Lorenzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.